Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.
The economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts is described. The pharmacodynamics of novel meropenem dosing regimens were compared with FDA-approved regimens by using Monte Carlo simulation with 5000 subjects. Using the meropenem NCCLS- susceptibility breakpoin...
| Publicado en: | American Journal of Health-System Pharmacy Vol. 60; no. 6; pp. 565 - 566 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Oxford University Press / USA
3/15/2003
|
| Acceso en línea: | Ver este registro en EBSCOhost |